Renin-Angiotensin-System (RAS)-Acting Agents Market Report 2025

The renin-angiotensin-system (RAS)-acting agents market size has grown steadily in recent years. It will grow from $5.82 billion in 2024 to $6.11 billion in 2025 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to the growing prevalence of hypertension, increasing incidence of cardiovascular diseases, rising aging population, increasing awareness about blood pressure management, strong clinical research support, and regulatory approvals for new drugs.

The renin-angiotensin-system (RAS)-acting agents market size is expected to see strong growth in the next few years. It will grow to $7.55 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to a growing focus on personalized treatment, rising demand for fixed-dose combinations, increasing investment in cardiovascular research, growing healthcare access in emerging markets, and rising prevalence of lifestyle-related diseases. Major trends in the forecast period include artificial intelligence (AI)-driven drug development, nanotechnology-based drug delivery, personalized medicine advancements, blockchain for secure clinical data, wearable biosensors for hypertension monitoring, and digital twin technology for patient modeling.

The forecast of 5.4% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers may hamper U.S. cardiology departments by inflating prices oangiotensin-converting enzyme inhibitors and angiotensin receptor blockers manufactured in Germany and Switzerland, resulting in limited hypertension management options and higher cardiovascular care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of hypertension is expected to drive the expansion of the renin-angiotensin system (RAS)-acting agents market in the coming years. Hypertension, or high blood pressure, is a chronic condition in which the force of blood against the artery walls is consistently too high. The rise in hypertension is largely due to unhealthy diets, particularly those rich in salt and processed foods, which contribute to higher blood pressure and increased strain on the cardiovascular system. RAS-acting agents help mitigate hypertension by regulating blood pressure through the inhibition of angiotensin II, a hormone that constricts blood vessels and increases fluid retention. By promoting vasodilation and reducing blood pressure, these agents help manage hypertension. For example, in October 2024, the Australian Bureau of Statistics reported that 11.6% (3 million) of Australians had hypertension in 2022, with similar rates observed for males (11.7%) and females (11.6%). Thus, the rising prevalence of hypertension is driving the growth of the RAS-acting agents market.

Key players in the RAS-acting agents market are focusing on developing novel inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors, to improve efficacy, minimize side effects, enhance patient compliance, and address hypertension, heart failure, and kidney diseases. ACE inhibitors work by lowering blood pressure through the blockage of the enzyme responsible for converting angiotensin I to angiotensin II, a substance that narrows blood vessels. For example, in November 2023, Proveca Ltd., a UK-based pharmaceutical company, received a grant from the European Commission for pediatric use marketing authorization (PUMA) for Aqumeldi (enalapril maleate) orodispersible tablets, which are indicated for the treatment of heart failure in children aged from birth to under 18 years. Aqumeldi, an ACE inhibitor, treats pediatric heart failure by preventing the conversion of angiotensin I to angiotensin II, thereby relaxing blood vessels, improving blood flow, and reducing the heart's workload.

In February 2023, AstraZeneca, a UK-based pharmaceutical company, acquired CinCor Pharma for $1.3 billion. Through this acquisition, AstraZeneca aims to strengthen its cardiorenal pipeline by adding CinCor’s lead drug, baxdrostat (CIN-107), a selective aldosterone synthase inhibitor (ASI) designed to reduce blood pressure in treatment-resistant hypertension. CinCor Pharma, a U.S.-based biopharmaceutical company, is focused on developing RAS-acting agents, including baxdrostat, which targets resistant hypertension.

Major players in the renin-angiotensin-system (RAS)-acting agents market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sandoz International GmbH, Astellas Pharma Inc., Bausch Health Companies Inc., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Biocon Limited, Daiichi Sankyo Company Limited, Glenmark Pharmaceuticals Ltd., and Torrent Pharmaceuticals Ltd.

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in renin-angiotensin system (RAS)-acting agents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the renin-angiotensin system (RAS)-acting agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The renin-angiotensin system (RAS)-acting agents market consists of sales of enalapril, lisinopril, ramipril, and captopril. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The renin-angiotensin-system (RAS)-acting agents market research report is one of a series of new reports that provides renin-angiotensin-system (RAS)-acting agents market statistics, including renin-angiotensin-system (RAS)-acting agents industry global market size, regional shares, competitors with a renin-angiotensin-system (RAS)-acting agents market share, detailed renin-angiotensin-system (RAS)-acting agents market segments, market trends and opportunities, and any further data you may need to thrive in the renin-angiotensin-system (RAS)-acting agents industry. This renin-angiotensin-system (RAS)-acting agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Renin-angiotensin system (RAS)-acting agents are a group of medications designed to regulate blood pressure, fluid balance, and vascular resistance by targeting different components of the renin-angiotensin system, which plays a vital role in cardiovascular and renal function. These agents are frequently prescribed for conditions such as hypertension, heart failure, and chronic kidney disease, either by blocking the production of angiotensin II or inhibiting its effects on blood vessels.

The primary classes of drugs in the renin-angiotensin system (RAS)-acting agents include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), renin inhibitors, aldosterone antagonists, and others. ACE inhibitors are medications that block the enzyme responsible for converting angiotensin I into angiotensin II, a substance that narrows blood vessels and raises blood pressure. They are used for various indications such as hypertension, heart failure, chronic kidney disease, diabetic nephropathy, and coronary artery disease. These drugs are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics, catering to various end users, including hospitals, research institutes, pharmaceutical companies, and others.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.